PHIBRO ANIMAL HEALTH CORPPAHCEarnings & Financial Report
Phibro Animal Health Corporation is an American animal health and mineral nutrition company. Its products include antibacterials, anticoccidials, anthelmintics, as well as animal nutrition and vaccines for livestock. The company operates through three segments Mineral Nutrition, Performance Materials, and Animal Health, from which most of its revenue is derived. The company operates in the United States, Latin America, Canada, Europe, Middle East, Africa, and Asia-Pacific. It is incorporated ...
PAHC Q2 2026 Key Financial Metrics
Revenue
$373.9M
Gross Profit
$132.7M
Operating Profit
$50.3M
Net Profit
$27.5M
Gross Margin
35.5%
Operating Margin
13.5%
Net Margin
7.3%
YoY Growth
20.9%
EPS
$0.67
Financial Flow
PHIBRO ANIMAL HEALTH CORP Q2 2026 Financial Summary
PHIBRO ANIMAL HEALTH CORP reported revenue of $373.9M for Q2 2026, with a net profit of $27.5M (7.3% margin). Cost of goods sold was $241.3M, operating expenses totaled $82.3M.
Key Financial Metrics
| Total Revenue | $373.9M |
|---|---|
| Net Profit | $27.5M |
| Gross Margin | 35.5% |
| Operating Margin | 13.5% |
| Report Period | Q2 2026 |
PHIBRO ANIMAL HEALTH CORP Annual Revenue by Year
PHIBRO ANIMAL HEALTH CORP annual revenue history includes year-by-year totals (for example, 2025 revenue was $1.3B).
| Year | Annual Revenue |
|---|---|
| 2025 | $1.3B |
| 2024 | $1.0B |
| 2023 | $977.9M |
| 2022 | $942.3M |
Income Statement
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $263.2M | $273.2M | $260.4M | $309.3M | $347.8M | $378.7M | $363.9M | $373.9M |
| YoY Growth | 7.1% | 7.1% | 12.6% | 23.7% | 32.1% | 38.6% | 39.7% | 20.9% |
Balance Sheet
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $979.0M | $982.2M | $966.3M | $1.29B | $1.32B | $1.36B | $1.39B | $1.41B |
| Liabilities | $708.9M | $725.5M | $707.8M | $1.04B | $1.05B | $1.08B | $1.07B | $1.07B |
| Equity | $270.1M | $256.6M | $258.5M | $246.8M | $266.0M | $285.7M | $311.7M | $332.4M |
Cash Flow
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $11.4M | $28.4M | $12.6M | $3.1M | $43.2M | $21.3M | $9.3M | $19.4M |